With the emergence of novel potassium-binding agents, it is possible that clinicians will attempt to control serum potassium rather than withdraw ACE/ARB therapy, particularly in patients with underlying cardiovascular diseasea.
科研之友
微信
新浪微博
Facebook
分享链接
